Bron: Jemsek Speciality Clinic (U.S.A.), Newsletter September 2013
Baxter Healthcare Corporation, in collaboration with Baxter Innovations GmbH, is engaged in an interventional, two-phase study to investigate the safety and efficacy in provoking an immune response using different dosages of a new Lyme Borreliosis vaccine. This vaccine utilizes OspA, a protein found on the outer membrane of Borrelia burgdorferi, the most notable infectious agent responsible for Lyme Borreliosis Complex. The study will look at the vaccine's effects in healthy subjects aged 18 to 70 years.
The study is primarily investigating antibody response to the vaccine 28 days after the third vaccination, as well as frequency and severity of reactions at the injection site and body-wide reactions within seven days after each vaccination. The study will also focus on various measures of antibody response after each vaccination, as well as examining any adverse reactions subjects may have to the vaccine.
Completion of the study is anticipated for November 2014. For more details, visit: Clinical Trials.